Skip to main content
. 2016 Feb 18;10:5–11. doi: 10.4137/BCBCR.S32785

Table 3.

Median survival (months) for patients vaccinated with either the nonemulsive or the emulsive formulation according to the site of metastases.

SITE OF METASTASES FORMULATION GLOBAL
NON EMULSIVE-SC EMULSIVE-IM
Non visceral n = 45 31,633 (n = 24) 16,533 (n = 21) 22,533
Visceral n = 48 21,033 (n = 24) 6,267 (n = 24) 8,800
Non visceral (log rank P = 0.118)/HR (95% CI): 0.535 (0.241–1.186)
Visceral (log rank P = 0.005)/HR (95% CI): 0.375 (0.184–0.766)